Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.

Influenza and Other Respiratory Viruses
Motokazu KatoTakuma Bando

Abstract

The efficacy of neuraminidase inhibitors on improvement of respiratory symptoms triggered by influenza in patients with pre-existing chronic respiratory diseases is unknown. This 2-week, randomized, open-label study evaluated intravenous peramivir 600 mg on two consecutive days (peramivir-repeat), peramivir 300 mg single dose (peramivir-single), and oral oseltamivir 75 mg twice daily for 5 days in patients with confirmed influenza and chronic respiratory diseases. Patients recorded symptom scores daily. The primary endpoint of cumulative area of time vs symptoms (CATVS) was expressed as an index value of area under the curve vs time of the total score of cough, sore throat, and nasal congestion from baseline to 2 weeks. Of 214 randomized patients, 209 (56% female, 77% aged <65 years, 94% outpatients, 91% bronchial asthma, 62% influenza A) received ≥1 dose of study drug. Mean (standard deviation) CATVS was similar for peramivir-repeat (782.78 [487.17]) vs peramivir-single (717.35 [347.55]; P = .4371), and for peramivir-repeat vs oseltamivir (856.34 [404.99]; P = 1.00). However, CATVS was significantly shorter for peramivir-single vs oseltamivir, with an estimated treatment difference (TD) of -145.07 (95% confidence interval: -28...Continue Reading

References

Oct 29, 2005·The Lancet Infectious Diseases·Ron Eccles
Dec 6, 2005·Antiviral Research·Shanta BantiaPooran Chand
Apr 6, 2011·Antimicrobial Agents and Chemotherapy·Shigeru KohnoUNKNOWN S-021812 Clinical Study Group
Aug 22, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akira Watanabe
Sep 12, 2012·Pulmonary Medicine·Mutsuo Yamaya
Oct 8, 2013·Frontiers in Microbiology·Daisuke KuraiHajime Takizawa
Sep 5, 2014·Chest·Brendan J CanningUNKNOWN CHEST Expert Cough Panel
Aug 9, 2016·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Takuji KomedaJingoro Shimada
Feb 16, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sudhir VenkatesanJonathan S Nguyen-Van-Tam
Jul 20, 2017·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Kazufumi TakamatsuAtsuko Hata
Sep 16, 2017·Infectious Disease Clinics of North America·H Keipp Talbot
Sep 25, 2017·Allergology International : Official Journal of the Japanese Society of Allergology·Yasuhiro Gon, Shu Hashimoto
Jun 14, 2019·Critical Care : the Official Journal of the Critical Care Forum·Eric J ChowTimothy M Uyeki
Jul 22, 2019·Critical Care : the Official Journal of the Critical Care Forum·Andre C Kalil, Paul G Thomas

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.